Anthony Drager
About Anthony Drager
Anthony Drager serves as the Executive Director and Head of Pharmaceutical Sciences at Venatorx Pharmaceuticals, Inc., and has held various roles in the pharmaceutical industry, including significant positions at Teva Pharmaceuticals and The Dow Chemical Company. He holds a Ph.D. in Organic Chemistry with a focus on nanotechnology and has been an adjunct professor at Millersville University since 2007.
Current Role at Venatorx Pharmaceuticals
Anthony Drager serves as the Executive Director and Head of Pharmaceutical Sciences at Venatorx Pharmaceuticals, Inc. since 2018. In this role, he oversees the pharmaceutical sciences department, focusing on the development of drug candidates. His responsibilities include directing formulation development efforts from IND enabling activities through NDA filing. His expertise in aerosol technology, nanotechnology, polymerization, microemulsions, and colloids supports the company's mission to advance innovative therapies.
Academic Background and Education
Anthony Drager holds a Doctor of Philosophy (Ph.D.) in Organic Chemistry with an emphasis in nanotechnology from the University of Arizona, where he studied from 1996 to 2001. He also earned a Bachelor's Degree in Chemistry from Millersville University of Pennsylvania, completing his studies there from 1990 to 1994. Additionally, he has been an Adjunct Professor of Chemistry at Millersville University since 2007, contributing to the academic community for 17 years.
Professional Experience at Teva Pharmaceuticals
Prior to his current role, Anthony Drager worked at Teva Pharmaceuticals as Associate Director of Formulation Development and Drug Delivery Technologies from 2004 to 2018. During his 14 years at Teva, he directed various formulation development projects, enhancing his expertise in drug delivery systems and formulation strategies.
Previous Experience at The Dow Chemical Company
Anthony Drager began his career as a Formulation Chemist at The Dow Chemical Company, where he worked from 2001 to 2004. His experience at Dow provided him with foundational skills in formulation chemistry, which he later applied in his roles at Teva Pharmaceuticals and Venatorx Pharmaceuticals.